Latest News
Latest News
SABR may be a new standard of care for primary RCC that is not suitable for surgery, according to a presentation at ASTRO 2023.
Nivolumab plus brentuximab vedotin, followed by ISRT, appears safe and effective for low-risk, relapsed classical Hodgkin lymphoma.
Proton pump inhibitor (PPI) use may negatively impact chemotherapy outcomes in patients with endometrial cancer, a study suggests.
Takeda is initiating a voluntary withdrawal of Exkivity (mobocertinib) from the US market, following negative results from a phase 3 trial.
The FDA has cleared Invitae Common Hereditary Cancers Panel, a diagnostic test that detects hundreds of hereditary cancer gene variants.
Pharmaceutical companies have agreed to negotiate prices for 10 drugs.
First-line treatment guided by biomarker testing results improves survival in patients with advanced non-small cell lung cancer, a study suggests.
Researchers have identified first-line treatment regimens that appear to be associated with the best outcomes in advanced, unresectable ESCC.
New research suggests that, in the United States, the use of palliative care for metastatic breast cancer varies by race.
Caregivers of adult cancer patients are not typically screened for distress, a new study suggests.
Loading...
Loading...